|
| |
CurisThis website contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Curis' future financial position, business strategy and plans and objectives of management for future operations. We may use such words as "believes," "expects," "anticipates," "plans," "estimates," and similar expressions to identify these forward-looking statements. There are a number of important factors that could cause Curis' actual results to differ materially from these indicated by such forward-looking statements, including those risk factors identified in the filings that Curis' makes from time to time with the SEC (click here to access SEC filings and risk factors contained herein). Curis disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date such statement was first made.
Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to create new medicines, primarily for cancer. In expanding its drug development efforts in the field of cancer through its Targeted Cancer Drug Development Platform, the Company is building upon its previous experiences in targeting signaling pathways in the areas of cancer, neurological disease and cardiovascular disease.
| Contact Details: |
| 61 Moulton Street |
| Cambridge |
| MA |
| 02138 |
| United States of America |
| Tel: | 617 503 6500 |
| Fax: | 617 503 6501 |
| Email: | |
| WWW: | www.curis.com/
|
|
Loading...
|
Recent Publications by Curis: |  |
CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy.
PURPOSE: We designed and synthesized CUDC-305, an HSP90 inhibitor of the... | 2nd September, 2009
| Curis, Inc, Cambridge,
| Clin Cancer Res. 2009 Jun 15;15(12):4046-57. Epub 2009 Jun 9.
DOI Direct Link |
Mathematical modeling in metal metabolism: overview and perspectives.
A review of mathematical modeling in metal metabolism is presented. Both... | 15th July, 2009
| Laboratoire de biomathematiques, E. A. 2498 & Plateau iB2, Departement
| Biochimie. 2009 Oct;91(10):1238-54. Epub 2009 Jul 9.
DOI Direct Link |
NAD and axon degeneration: From the Wlds gene to neurochemistry.
Neurodegenerative diseases have become a global issue due to the aging... | 18th April, 2009
| Curis Inc., Cambridge, MA, USA; Children's Hospital, Harvard Medical
| Cell Adh Migr. 2009 Jan 25;3(1).
|
Citrulline and the gut.
PURPOSE OF REVIEW: Citrulline, a nonprotein amino acid, is an important... | 6th December, 2007
| Laboratoire de Biomathematiques, Faculte de Pharmacie, Universite Paris
| Curr Opin Clin Nutr Metab Care. 2007 Sep;10(5):620-6.
DOI Direct Link |
Lactosamine modulates the rate of migration of GnRH neurons during mouse development.
Gonadotropin-releasing hormone (GnRH) neurons are derived from progenitor... | 2nd November, 2006
| Curis Inc., Cambridge, MA 02138, USA.
| Eur J Neurosci. 2006 Aug;24(3):654-60.
DOI Direct Link |
→View more Curis research publications. |
Press Releases on Curis:
|
 |
| Reportlinker Adds Regenerative Medicine - Global Market Trends |
25th November, 2009 |
Reportlinker |
NEW YORK, Nov. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Regenerative Medicine - Global Market Trends
http://www.reportlinker.com
|
| AlphaVax Announces New Vice President of Regulatory, Quality and Clinical Operations |
16th February, 2009 |
AlphaVax |
RESEARCH TRIANGLE PARK, N.C., Feb. 16 /PRNewswire/ -- AlphaVax announced today that it has hired Lynn Baird, PhD, as Vice President of Regulatory, Quality and Clinical Operations. In this capacity
|
| Cequent Names Ted Hibben Chief Business Officer |
12th January, 2009 |
Cequent Pharmaceuticals |
CAMBRIDGE, Mass., Jan. 12 /PRNewswire/ -- Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, announced that
|
| Biotech Insight Alert 16th May 2004 |
1st May, 2004 |
Biotech Insight |
Biotech Insight Alert 16th May 2004
May
16th 2004: The last few
|
| BiotechTracker: Curis Approaches the Starting Gate |
1st January, 1970 |
Biotracker |
BiotechTracker:
Curis Approaches the Starting Gate
September 02, 2003 On
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 313 times since April 2007, the link to the organisation's website has been followed 51 times Search for more companies in Cambridge Search for more companies in MA This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Curis |
